Security
WORK Medical Technology Group LTD Class A Ordinary Shares · WOK
WOKNASDAQCommon stockCurrentCIK 1929783Updated Oct 6, 2026
Name history
WORK Medical Technology Group LTD · through Aug 24, 2026WORK Medical Technology LTD · through Jun 23, 2022
WOK price & chart
Loading TradingView…
NASDAQ:WOK on TradingView ↗About the company
WORK Medical Technology Group LTD, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, is a supplier of medical devices that develops and manufactures Class I and II medical devices and sells Class I and II disposable medical devices through operating subsidiaries in China. The Company has a diverse product portfolio comprising 23 products, including customized and multifunctional masks and other medical consumables. All the products have been sold in 34 provincial-level administrative regions in China, with 15 of them sold in more than 30 countries worldwide. The Company has received a number of quality-related manufacturing designations and has registered 17 products with the U.S. Food and Drug Administration allowing their products to enter the U.S. market. For more information, please visit the Company’s website: https://www.workmedtech.com/corporate.
In the news
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q2 2025 | FY 2025 | FY 2024 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 34,713,064Source | 33,156,256Source | 36,250,563Source |
| Property, Plant and Equipment, NetUSD | 10,828,725Source | 10,587,852Source | 11,372,485Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 975,622Source | 959,116Source | 1,044,062Source |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 1,995,767Source | 4,088,599Source | 6,557,605Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 876,674Source | 615,838Source | 1,648,797Source |
| Inventory, NetUSD | 2,975,922Source | 2,455,477Source | 3,183,951Source |
| Assets, CurrentUSD | 21,579,215Source | 20,455,133Source | 20,827,220Source |
| Prepaid Expense and Other Assets, CurrentUSD | 213,994Source | 1,280,790Source | 1,632,702Source |
| Operating Lease, Right-of-Use AssetUSD | 26,080Source | 26,060Source | — |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 18,996,098Source | 11,991,525Source | 20,180,190Source |
| Stockholders’ equity: | |||
| Common Stock, Value, IssuedUSD | — | — | 7,296Source |
| Retained Earnings (Accumulated Deficit)USD | 6,089,174Source | 4,958,991Source | 6,076,018Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -659,984Source | -608,729Source | -408,465Source |
| Stockholders' Equity Attributable to ParentUSD | 12,947,563Source | 18,338,941Source | 13,185,926Source |
| Additional Paid in Capital, Common StockUSD | 6,617,596Source | 13,043,402Source | 6,617,596Source |
| Liabilities and EquityUSD | 34,713,064Source | 33,156,256Source | 36,250,563Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 18,978,893Source | 11,971,466Source | 20,180,190Source |
| Operating Lease, Liability, CurrentUSD | 5,335Source | 6,743Source | — |
| Accounts Payable, CurrentUSD | 1,467,998Source | 1,724,551Source | 1,497,152Source |
| Operating Lease, Liability, NoncurrentUSD | 17,205Source | 18,756Source | — |
| Deferred Income Tax Liabilities, NetUSD | — | 1,303Source | — |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 2,769,403Source | 2,825,790Source | 2,884,447Source |
cash flow · annual statements
| Line item | Q2 2025 | Q2 2024 | FY 2025 | FY 2024 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -1,201,023Source | -3,540,409Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | —Source | —Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | -1,022,554Source | -1,815,361Source |
| Increase (Decrease) in InventoriesUSD | — | — | -568,669Source | -1,576,799Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | 245,499Source | -2,553,902Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | 111,151Source | -46,044Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | 6,244,285Source | -2,228,087Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | -7,607,719Source | -9,064,079Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | 1,332,507Source | 9,225,094Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | -898,212Source | 15,657,024Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | -2,469,006Source | 4,920,322Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 1,995,767Source | 1,080,639Source | 4,088,599Source | 6,557,605Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | 508,519Source | 543,753Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | -207,360Source | 555,464Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | — | — | 69,166Source | 56,923Source |
| Deferred Other Tax Expense (Benefit)USD | — | — | 111,151Source | -42,266Source |
| DepreciationUSD | — | — | 848,658Source | 1,336,879Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | -178,381Source | -42,504Source |
| General and Administrative ExpenseUSD | — | — | 2,327,352Source | 4,558,041Source |
| Income Tax Expense (Benefit)USD | — | — | 119,053Source | -125,291Source |
| InterestExpenseNonoperatingUSD | — | — | 503,519Source | 557,571Source |
| Inventory Write-downUSD | — | — | 105,599Source | 762Source |
| Investment Income, InterestUSD | — | — | 181,682Source | 11,727Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,072,667Source | -3,492,318Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -128,356Source | -48,091Source |
| Nonoperating Income (Expense)USD | — | — | 1,414,090Source | 379,485Source |
| Operating ExpensesUSD | — | — | 4,840,914Source | 6,913,571Source |
| Other Nonoperating Income (Expense)USD | — | — | 135,400Source | 578,758Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | 17,954,939Source | — |
| Proceeds from (Payments to) Noncontrolling InterestsUSD | — | — | — | 2,767,032Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 9,848,715Source | 11,506,440Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Other Nonoperating Income (Expense)USD | 135,400Source | 578,758Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -1,081,970Source | -3,665,700Source |
| Income Tax Expense (Benefit)USD | 119,053Source | -125,291Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -128,356Source | -48,091Source |
| Net Income (Loss) Attributable to ParentUSD | -1,072,667Source | -3,492,318Source |
| Earnings Per Share, BasicUSD per share | -0.04Source | -0.27Source |
| Earnings Per Share, DilutedUSD per share | -0.04Source | -0.27Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 28,983,269Source | 12,705,011Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 28,983,269Source | 12,705,011Source |
| Interest Expense (non-operating)USD | 503,519Source | 557,571Source |
| Additional Financial Items | ||
| Amortization of Intangible AssetsUSD | 69,166Source | 56,923Source |
| Current Income Tax Expense (Benefit)USD | 7,902Source | -83,025Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 923,108Source | 1,410,452Source |
| General and Administrative ExpenseUSD | 2,327,352Source | 4,558,041Source |
| Gross ProfitUSD | 2,344,854Source | 2,868,386Source |
| Interest Expense, DebtUSD | 503,519Source | — |
| Investment Income, InterestUSD | 181,682Source | 11,727Source |
| Nonoperating Income (Expense)USD | 1,414,090Source | 379,485Source |
| Operating ExpensesUSD | 4,840,914Source | 6,913,571Source |
| Research and Development ExpenseUSD | 435,311Source | 302,511Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 9,848,715Source | 11,506,440Source |
| Selling ExpenseUSD | 2,078,251Source | 2,053,019Source |
Filing attachments
ea030193201ex99-1.htm · 6-K · 2026-08-14
Exhibit 99.1 WORK MEDICAL TECHNOLOGY GROUP LTD UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (In U.S. dollars, except for otherwise noted) As As …
Read attachment ↗ea030193201ex99-2.htm · 6-K · 2026-08-14
Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Financial Highlights ( all results compared to the prior fiscal period unless otherwise noted ) Revenues were $5.4 million, representing an increase of 19.1% Gross margin was 19.1%, compared with 34.4% Net loss was $3,461,214, compared with net loss of $29,425 The Group has cash and cash equivalents of approximately $3.25 million as of March 31, 2026, compared to approximately…
Read attachment ↗ea030204701ex99-1.htm · 6-K · 2026-08-14
Exhibit 99.1 WORK Medical Announces 1-for-100 Reverse Stock Split Effective June 18, 2026 Auckland, New Zealand, June 16, 2026 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, today announced that it will effect a reverse stock split of its Class A ordinary shares of par value US$0.00001 each and Class B ordinary shares of par value US$0.00001 each at a ratio of 1-for-100, effective on June 18, 2026 (…
Read attachment ↗ea029376901ex99-1.htm · 6-K · 2026-06-05
Exhibit 99.1 WORK Medical Technology Group Establishes U.S. Subsidiary to Advance Global Expansion and Reinforce Long-Term Growth Strategy Hangzhou, China, June 3, 2026 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical”, the “Company” or “we”), a supplier of medical devices in China today announced the establishment of its U.S. subsidiary, Work Bio Technologies Ltd (“WBT” or the “Subsidiary”), marking a strategic milestone in the Company’s global expansion init…
Read attachment ↗ea029376901ex99-2.htm · 6-K · 2026-06-05
Exhibit 99.2 WORK Medical Technology Group Participated in 2026 CBA-China Annual Conference Deepening Engagement with the Global Biopharmaceutical Community Auckland, New Zealand, June 5, 2026 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical”, the “Company” or “we”), a supplier of medical devices in China,, today announced its participation as a partner and exhibitor at the 2026 CBA-China Annual Conference (the “Conference”), held on May 8 to 10, 2026 in Wuxi…
Read attachment ↗ea027615701ex99-1_work.htm · 6-K · 2026-02-10
Exhibit 99.1 WORK MEDICAL TECHNOLOGY GROUP LTD(an exempted company with limited liability incorporated in the Cayman Islands) (Nasdaq: WOK) NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN THAT the annual general meeting (the “Meeting”) of the holders (each a “Shareholder”, and collectively, the “Shareholders”) of the Class A ordinary shares and Class B ordinary shares (collectively, the “Ordinary Shares”) of WORK Medical Technology Group LTD (the “Company”) will be he…
Read attachment ↗